Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Status:
RECRUITING
Trial end date:
2028-11-30
Target enrollment:
Participant gender:
Summary
This study is an open-label, randomized controlled, multicenter, phase III clinical trial
Phase:
PHASE3
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators:
Beijing 302 Hospital Beijing Ditan Hospital Nanfang Hospital, Southern Medical University Peking University People's Hospital The Third Affiliated Hospital of Naval Medical University